Axicabtagene ciloleucel
FDA Eliminates REMS for 6 CAR T-Cell Immunotherapies
The FDA announced it has eliminated the Risk Evaluation and Mitigation Strategies (REMS) for six currently approved ...
JULY 8, 2025
CAR-T Therapy Associated With Frequent Reports of Cardiopulmonary AEs
Chimeric antigen receptor T-cell therapy—genetically engineered immune cells programmed to identify tumor ...
JANUARY 28, 2022
FDA Approves Yescarta for Relapsed or Refractory Follicular Lymphoma
The FDA has approved axicabtagene ciloleucel (Kite Pharma) for the treatment of adults with relapsed or refractory ...
MARCH 9, 2021
CAR T-Cell Rx Effective in Refractory Lymphoma
Chicago—In patients with refractory diffuse large B-cell lymphoma (DLBCL), response rates with axicabtagene ...
OCTOBER 3, 2018
Nathan Singh, MD, and David Porter, MD: How I Manage CAR T-Cell Therapy
The human immune system has powerful potential to fight cancer, mediated in large part by T lymphocytes. Autologous ...
FEBRUARY 28, 2018
FDA Approves CAR Therapy Yescarta To Treat Large B-Cell Lymphomas
Axicabtagene ciloleucel (Yescarta, Kite Pharma) has been approved to treat adults with relapsed or refractory ...
OCTOBER 24, 2017